Hypothesis

Senescent cells in the aging cochlea exhibit a temporal switch in their secretory profile: early‑stage senescence releases a SASP enriched in trophic and angiogenic factors that support spiral ganglion neuron (SGN) survival and stria vascularis function, whereas chronic senescence shifts the SASP toward pro‑inflammatory mediators that exacerbate hair cell loss, SGN degeneration, and endocochlear potential decline. Consequently, blunt senolytic ablation removes both detrimental and beneficial secretions, potentially worsening hearing loss if administered before the pathogenic switch.

Mechanistic Rationale

• Early protective SASP: In vitro oxidative stress models show that transient p21‑positive senescent fibrocyte‑like cells upregulate IGF‑1, VEGF, and TGF‑β1, which promote SGN neurite outgrowth and maintain potassium recycling in the stria vascularis (2). These factors parallel the regenerative SASP observed in other tissues where senescent cells aid wound healing.
• Transition to pathogenic SASP: Persistent DNA damage and mitochondrial ROS amplify NF‑κB signaling, converting the secretome to IL‑1α, IL‑6, CCL2, and MMP‑9. This inflammaging SASP recruits neutrophils and macrophages, driving the cytokine milieu linked to SGN apoptosis and stria atrophy (3).
• Evidence of temporal dichotomy: Studies reporting senescent cell accumulation correlating with hearing loss primarily examined end‑point aged tissues, capturing the late pathogenic stage (1). No data exist on the SASP composition of early senescent cochlear cells, creating a knowledge gap that this hypothesis addresses.
• Therapeutic implication: Interventions that boost cAMP‑MFN2 signaling reduce senescence markers and improve function, suggesting that modulating senescence—rather than indiscriminate clearance—may preserve beneficial SASP while limiting harmful effects (5).

Testable Predictions

1. Cochlear tissues from mice at 4 months (pre‑presbycusis) will show higher IGF‑1/VEGF expression in p21⁺ cells than tissues from 18 months (presbycusis).
2. Early‑stage senolytic treatment (dasatinib+quercetin at 3 months) will reduce IGF‑1/VEGF levels and accelerate SGN loss compared with vehicle, whereas late‑stage treatment (at 15 months) will improve SGN survival and endocochlear potential.
3. Conditioned medium from early‑senescent cochlear explants will protect cultured SGNs from oxidative insult, an effect blocked by IGF‑1 or VEGF neutralizing antibodies; medium from late‑senescent explants will exacerbate SGN death, an effect mitigated by IL‑1RA or CCR2 antagonists.

Experimental Approach

• Animal model: C57BL/6J mice stratified by age (3, 6, 12, 18 months).
• Senescence identification: p21 immunostaining combined with SA‑β‑gal fluorescence; flow cytometry to isolate p21⁺ fibrocyte‑like cells from stria vascularis and SGN compartments.
• SASP profiling: Multiplex ELISA or proteomics on lysates and conditioned media from sorted senescent cells to quantify IGF‑1, VEGF, IL‑6, CCL2, MMP‑9.
• Functional readouts: Auditory brainstem response (ABR) thresholds, distortion product otoacoustic emissions (DPOAEs), SGN density (neurofilament staining), endocochlear potential measurement, and stria vascularis morphology (Kir4.1 expression).
• Interventions: Dasatinib+quercetin administered via intraperitoneal injection on a 3‑day‑on/4‑day‑off schedule for 2 weeks at early vs. late timepoints; parallel groups receive IGF‑1/VEGF neutralizing antibodies or IL‑1RA/CCR2 antagonists.
• Statistical plan: Two‑way ANOVA (age × treatment) with post‑hoc Tukey test; significance set at p < 0.05. Power analysis indicates n = 8 per group to detect a 10 dB ABR shift with 80 % power.

Potential Impact

If validated, this hypothesis reframes senolytics from a blunt clearance strategy to a precision‑timed approach, emphasizing the need to biomarker‑guide interventions based on senescent cell phenotype. It also suggests that augmenting early protective SASP components (e.g., IGF‑1 delivery) could be a complementary strategy to preserve hearing in aging populations.